Cargando…

AB123. The clinical safety and efficacy of kidney-sparing surgery to treat the primary transitional cell carcinoma of ureter

OBJECTIVE: To evaluate the clinical safety and efficacy of kidney-sparing surgery to treat the primary transitional cell carcinoma of ureter. METHODS: The materials of 29 cases which underwent kidney-sparing surgery for treatment of the carcinoma of ureter were analyzed retrospectively. All the pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jianwen, Kang, Ning, Xing, Nianzeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708709/
http://dx.doi.org/10.3978/j.issn.2223-4683.2015.s123
_version_ 1782409527612669952
author Wang, Jianwen
Kang, Ning
Xing, Nianzeng
author_facet Wang, Jianwen
Kang, Ning
Xing, Nianzeng
author_sort Wang, Jianwen
collection PubMed
description OBJECTIVE: To evaluate the clinical safety and efficacy of kidney-sparing surgery to treat the primary transitional cell carcinoma of ureter. METHODS: The materials of 29 cases which underwent kidney-sparing surgery for treatment of the carcinoma of ureter were analyzed retrospectively. All the patients underwent kidney-sparing surgeries: 3 cases for endoscopy ablation, 8 cases for laparoscopy (5 direct ureterocystoneostomies, 3 reimplantations on Boari flap bladder), 18 cases for open surgeries (10 direct ureterocystoneostomies, 5 reimplantations on Boari flap bladder, and 3 end-to-end anastomoses). All the patients underwent regular intravesical instillation and close follow-up post-operation, 3 cases also received intravenous chemotherapy. RESULTS: All the pathology was transitional cell carcinoma, including 4-papillary urothelial neoplasms of low malignant potential, 13 low-grade papillary urothelial carcinoma, and 12 high-grade papillary urothelial carcinoma. Clinical stage was classified T1 (5), T2 (18) and T3 (6). The recurrence in bladder and ipsilateral ureter was 10.3% and 3.4%, respectively. Two cases suffered from urine leak, 5 cases had mild hydronephrosis, and 3 cases died of heart and lung diseases. The recurrence in bladder was 5.9% in low-grade tumors, and the recurrence in bladder and ipsilateral ureter was 11.1% in T2 tumors, 33.3% in T3 tumors. CONCLUSIONS: Kidney-sparing surgery is a feasible treatment option for the selected patients with unifocal middle or distal ureteric carcinoma at low grade or without invasive aspect on CT. Laparoscopic ureterocystoneostomy or endoscopic management had more minimally invasive advantages in the treatment. However, active surveillance should be done during the follow-up.
format Online
Article
Text
id pubmed-4708709
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-47087092016-01-26 AB123. The clinical safety and efficacy of kidney-sparing surgery to treat the primary transitional cell carcinoma of ureter Wang, Jianwen Kang, Ning Xing, Nianzeng Transl Androl Urol Moderated Poster Presentation OBJECTIVE: To evaluate the clinical safety and efficacy of kidney-sparing surgery to treat the primary transitional cell carcinoma of ureter. METHODS: The materials of 29 cases which underwent kidney-sparing surgery for treatment of the carcinoma of ureter were analyzed retrospectively. All the patients underwent kidney-sparing surgeries: 3 cases for endoscopy ablation, 8 cases for laparoscopy (5 direct ureterocystoneostomies, 3 reimplantations on Boari flap bladder), 18 cases for open surgeries (10 direct ureterocystoneostomies, 5 reimplantations on Boari flap bladder, and 3 end-to-end anastomoses). All the patients underwent regular intravesical instillation and close follow-up post-operation, 3 cases also received intravenous chemotherapy. RESULTS: All the pathology was transitional cell carcinoma, including 4-papillary urothelial neoplasms of low malignant potential, 13 low-grade papillary urothelial carcinoma, and 12 high-grade papillary urothelial carcinoma. Clinical stage was classified T1 (5), T2 (18) and T3 (6). The recurrence in bladder and ipsilateral ureter was 10.3% and 3.4%, respectively. Two cases suffered from urine leak, 5 cases had mild hydronephrosis, and 3 cases died of heart and lung diseases. The recurrence in bladder was 5.9% in low-grade tumors, and the recurrence in bladder and ipsilateral ureter was 11.1% in T2 tumors, 33.3% in T3 tumors. CONCLUSIONS: Kidney-sparing surgery is a feasible treatment option for the selected patients with unifocal middle or distal ureteric carcinoma at low grade or without invasive aspect on CT. Laparoscopic ureterocystoneostomy or endoscopic management had more minimally invasive advantages in the treatment. However, active surveillance should be done during the follow-up. AME Publishing Company 2015-08 /pmc/articles/PMC4708709/ http://dx.doi.org/10.3978/j.issn.2223-4683.2015.s123 Text en 2015 Translational Andrology and Urology. All rights reserved.
spellingShingle Moderated Poster Presentation
Wang, Jianwen
Kang, Ning
Xing, Nianzeng
AB123. The clinical safety and efficacy of kidney-sparing surgery to treat the primary transitional cell carcinoma of ureter
title AB123. The clinical safety and efficacy of kidney-sparing surgery to treat the primary transitional cell carcinoma of ureter
title_full AB123. The clinical safety and efficacy of kidney-sparing surgery to treat the primary transitional cell carcinoma of ureter
title_fullStr AB123. The clinical safety and efficacy of kidney-sparing surgery to treat the primary transitional cell carcinoma of ureter
title_full_unstemmed AB123. The clinical safety and efficacy of kidney-sparing surgery to treat the primary transitional cell carcinoma of ureter
title_short AB123. The clinical safety and efficacy of kidney-sparing surgery to treat the primary transitional cell carcinoma of ureter
title_sort ab123. the clinical safety and efficacy of kidney-sparing surgery to treat the primary transitional cell carcinoma of ureter
topic Moderated Poster Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708709/
http://dx.doi.org/10.3978/j.issn.2223-4683.2015.s123
work_keys_str_mv AT wangjianwen ab123theclinicalsafetyandefficacyofkidneysparingsurgerytotreattheprimarytransitionalcellcarcinomaofureter
AT kangning ab123theclinicalsafetyandefficacyofkidneysparingsurgerytotreattheprimarytransitionalcellcarcinomaofureter
AT xingnianzeng ab123theclinicalsafetyandefficacyofkidneysparingsurgerytotreattheprimarytransitionalcellcarcinomaofureter